Form 8-K - Current report:
SEC Accession No. 0001193125-25-134883
Filing Date
2025-06-04
Accepted
2025-06-04 16:05:15
Documents
12
Period of Report
2025-06-03
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d941283d8k.htm   iXBRL 8-K 31866
  Complete submission text file 0001193125-25-134883.txt   145920

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akro-20250603.xsd EX-101.SCH 2849
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20250603_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20250603_pre.xml EX-101.PRE 11260
14 EXTRACTED XBRL INSTANCE DOCUMENT d941283d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 251023112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)